Literature DB >> 20638029

Hepatitis B vaccination: disease and cancer prevention-a Taiwanese experience.

Mei Hwei Chang1.   

Abstract

Prevention is most cost effective toward successful control of hepatitis B virus (HBV) infection and its complications. It is particularly urgent where HBV infection and hepatocellular carcinoma (HCC) are prevalent. To achieve better results of primary HCC prevention globally, higher world coverage rates of HBV vaccine, better strategies against breakthrough infection/nonresponder, and good long-term protection are needed. With the universal hepatitis B vaccination program starting from neonates in most countries, HBV infection and its complications will be further reduced in this century. An effective decline in the incidence of HCC in adults is expected in the near future. The concept of a cancer preventive vaccine, using HBV as an example, can be applied further to other infectious agents and their related cancers. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20638029     DOI: 10.1016/j.cld.2010.05.010

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  5 in total

1.  Preparing for the availability of a partially effective HIV vaccine: some lessons from other licensed vaccines.

Authors:  Robert T Chen; Dale J Hu; Eileen Dunne; Michael Shaw; James I Mullins; Supachai Rerks-Ngarm
Journal:  Vaccine       Date:  2011-07-13       Impact factor: 3.641

Review 2.  Hepatitis B infection: current concepts and future challenges.

Authors:  G Nebbia; D Peppa; M K Maini
Journal:  QJM       Date:  2012-02

3.  Comparison of the accelerated and standard vaccination schedules against hepatitis B in healthcare workers.

Authors:  Keyghobad Ghadiri; Siavash Vaziri; Mandana Afsharian; Alireza Jahanbaksh; Faizolah Mansouri; Mansouri Sayad; Farid Najafi; Bahram Souri
Journal:  J Res Med Sci       Date:  2012-10       Impact factor: 1.852

4.  Infantile hepatitis B in immunized children: risk for fulminant hepatitis and long-term outcomes.

Authors:  Yu-Ru Tseng; Jia-Feng Wu; Man-Shan Kong; Fu-Chang Hu; Yao-Jong Yang; Chun-Yan Yeung; Fu-Chen Huang; I-Fei Huang; Yen-Hsuan Ni; Hong-Yuan Hsu; Mei-Hwei Chang; Huey-Ling Chen
Journal:  PLoS One       Date:  2014-11-07       Impact factor: 3.240

5.  Improvement in High-Grade Osteosarcoma Survival: Results from 202 Patients Treated at a Single Institution in Taiwan.

Authors:  Giun-Yi Hung; Hsiu-Ju Yen; Chueh-Chuan Yen; Po-Kuei Wu; Cheng-Fong Chen; Paul C-H Chen; Hung-Ta H Wu; Hong-Jen Chiou; Wei-Ming Chen
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.